Trial · NCT02241720
Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
NCT02241720, Phase 2, Terminated, University of Utah; results first posted 2017-10-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers. Trials, record NCT02241720. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02241720
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
- NCT number
- NCT02241720
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- University of Utah
- Conditions
- Upper GI Cancer
- Interventions
- regorafenib
- First posted
- 2014-09-16
- Last updated
- 2018-01-11
- Results first posted
- 2017-10-26
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Stable Disease at Eight Weeks Post-Treatment | 5 months - 3 months treatment and 8 weeks post end of treatment visit | Patients had disease assessed by CT scans. Stable Disease is defined by any response better than Progression as defined by RECIST 1.1. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Stable Disease at Eight Weeks Post-Treatment | 5 months - 3 months treatment and 8 weeks post end of treatment visit | 3 subjects did not complete an 8 week EOT visit for: Death, Patient W/D, AE. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Stable Disease at Eight Weeks Post-Treatment | Regorafenib Treatment | 2 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Regorafenib Treatment | 5 | |
| Overall Study | COMPLETED | Regorafenib Treatment | 1 | |
| Overall Study | NOT COMPLETED | Regorafenib Treatment | 4 |
Source ClinicalTrials.gov
Adverse events21
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Regorafenib Treatment | 3 | 5 | 3 |
| other | Hypertension | Vascular disorders | Regorafenib Treatment | 4 | 5 | 4 |
| other | deydration | Metabolism and nutrition disorders | Regorafenib Treatment | 2 | 5 | 2 |
| other | Abdominal pain | Gastrointestinal disorders | Regorafenib Treatment | 1 | 5 | 2 |
| other | hyperbilirubinemia | Investigations | Regorafenib Treatment | 1 | 5 | 1 |
| other | maculopapular rash | Skin and subcutaneous tissue disorders | Regorafenib Treatment | 1 | 5 | 2 |
| other | anemia | Blood and lymphatic system disorders | Regorafenib Treatment | 1 | 5 | 1 |
| other | hypothyroidism | Endocrine disorders | Regorafenib Treatment | 1 | 5 | 1 |
| other | dysphagia | Gastrointestinal disorders | Regorafenib Treatment | 2 | 5 | 2 |
| other | headache | Nervous system disorders | Regorafenib Treatment | 1 | 5 | 1 |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Regorafenib Treatment | ||
| Total, other adverse events | Regorafenib Treatment | 5 | 5 |
| Total, serious adverse events | Regorafenib Treatment | 3 | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02241720
GET https://conductscience.org/api/trials/v1/NCT02241720/events?page=2